Cosmos Health Inc. has announced its strategic entry into the U.S. market through a new manufacturing agreement with DolCas Biotech LLC, a New Jersey-based developer of nutraceutical ingredients. This collaboration marks a significant milestone for Cosmos Health as it begins U.S.-based production at GMP-certified facilities, enhancing its control over production processes and reducing risks associated with tariffs and cross-border logistics. The agreement with DolCas Biotech not only strengthens Cosmos Health's position in the premium nutraceuticals market but also supports its broader strategy of expanding its portfolio with scientifically backed ingredients. This partnership is seen as a key step in Cosmos Health's global growth strategy, under the leadership of CEO Greg Siokas, and aims to leverage DolCas's expertise in innovative, clinically validated formulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.